替吉奥（S-1）单药治疗既往未接受过化疗的老年转移性胰腺癌患者的疗效观察

Therapeutic Effect of Teggio(S-1) Monotherapy on Elderly Patients with Metastatic Pancreatic Cancer Who Have Not Received Chemotherapy

目的研究替吉奥(S-1)单药治疗既往未接受过化疗的老年转移性胰腺癌患者的疗效.方法根据双盲随机分组原则将于2016年1月-12月期间在中山大学附属佛山医院治疗的老年转移性胰腺癌患者80例,平分为对照组和观察组,对照组采取吉西他滨单药治疗,观察组实施S-1单药治疗.结果观察组临床总有效率(97.50%)高于对照组(P<0.05),观察组氨基转移酶升高、白细胞减少、中性粒细胞减少、血小板减少等4项不良反应发生率低于对照组(P<0.05).结论既往未接受过化疗的老年转移性胰腺癌患者采用替吉奥单药治疗安全有效.

Objective To study the efficacy of Teggio(S-1)in the treatment of elderly patients with metastatic pancreatic cancer who did not received chemotherapy.MethodsAccording to the "double-blind randomized grouping principle",80 patients with metastatic pancreatic cancer in the hospital from January to December,2018 were divided into control group and observation group,with40 cases in each group. The control group received Gemcitabine monotherapy treatment,and the observation group received the S-1 monotherapy. The clinical effects and adverse reactions of elderly patients with metastatic pancreatic cancer in the two groups were compared.ResultsThe total clinical effective rate(97.50%)of the elderly patients with metastatic pancreatic cancer was higher than that of the control group(P<0.05). The incidence of four adverse reactions,such as elevated aminotransferase,leukopenia,central neutropenia and thrombocytopenia,was lower in the observation group than in the control group(P<0.05).ConclusionThe patients with metastatic pancreatic cancer who have not received chemotherapy in the past are safe and effective with tegao monotherapy.